We appreciate the interest in our article shown by Miralles et al. Indeed, data collected so far regarding the application of low-dose recombinant interferon alfa to Kaposi's sarcoma appear inconclusive.
In a recently published report, Trattner et al1 injected interferon alfa intralesionally, with a dosage similar to ours, resulting, most probably, in a systemic distribution. Of 10 patients, only one showed a complete resolution of all lesions following a mere 3 weeks of treatment. A response of the injected lesion was noted in all but one patient; distant lesions exhibited no effect. The patients were treated for up to 8 weeks only, and a longer period of treatment might have resulted in a more favorable response, although even much lower doses given for a similar period of time (6 to 7 weeks) in a previous study2 resulted in some noticeable changes in distant lesions.
Since the submission of
Tur E, Brenner S. Low-Dose Recombinant Interferon Alfa-2a Treatment for Classic Kaposi's Sarcoma-Reply. Arch Dermatol. 1994;130(6):800-801. doi:10.1001/archderm.1994.01690060138024